Ataei B, Khodadoostan M, Pouria B and Adibi P. Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. J. Res. Pharm. Pract. (2016) 5(3): 166-170.
 Lok AS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. (2016) 63(1): 284-306.
 Agarwal K, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J. Hepatol. (2015) 62(3): 533-540.
 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. (2016) 63(1): 261-283.
 Bhatt PA. Being a clinical pharmacist: Expectations and outcomes. Indian J. Pharmacol. (2014) 46 (1): 1-2.
 Steiner JF and Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. (1997) 50 (1): 105-116.
 Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M and Alavian SM. Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis. Hepat. Mon. (2016) 16(4): e35577.
 Kayaaslan B and Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World. J. Hepatol. (2017) 9 (5): 227-241.
 Bedimo R, Maalouf NM, Zhang S, Drechsler H and Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. Aids. (2012) 26(7): 825-831.
 Gill US, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J. Infect. Dis. (2015) 211 (3): 374-382.
 Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. (2009) 49 (5 Suppl): S185-195.
 Langness JA, Nguyen M, Wieland A, Everson GT and Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World. J. Gastroenterol. (2017) 23 (9): 1618-1626.
 Martin MT and Faber DM. Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management. J. Clin. Pharm. Ther. (2016) 41(6): 645-649.
 Rodis JL and Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol. Nurs. (2010) 33(5): 368-373.
 Marino EL, Alvarez-Rubio L, Miro S, Modamio P, Banos F, Lastra CF and Alberdi-Leniz A. Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C. J. Manag. Care. Pharm. (2009) 15 (2): 147-150.
 Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI and Bates DW. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. Jama. (1999) 282 (3): 267-270.
 Jameson JP and VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann. Pharmacother. (2001) 35 (7-8): 835-840.
 Esmaily H and Saffaei A. Vitamin D Usage Among Iranian Population: A Toxicity Crisis is on the Way. Oman Med. J. (2019) 34 (2): 174-175.
 Krska J, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age. Ageing. (2001) 30(3): 205-211.
 Chumney EC and Robinson LC. The effects of pharmacist interventions on patients with polypharmacy. Pharmacy. practice. (2006) 4(3): 103-109.
 Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs Medical Center. Pharmacotherapy. (1998) 18(5): 1103-1111.
 Mokhtari F, Nikyar Z, Naeini BA, Esfahani AA and Rahmani S. Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients. J. Res. Med. Sci. (2014) 19 (8): 720-725.